Eumentis is a biopharmaceutical company focused on developing targeted pharmacological treatments for neuropsychiatric conditions, utilizing advanced drug formulation techniques. The company aims to improve patient outcomes by addressing the unmet medical needs in the treatment of mental health disorders.
Funding
$33.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
USFounders
Product
Problem
Many neuropsychiatric conditions lack effective pharmacological treatments, leading to unmet medical needs and suboptimal patient outcomes. Current treatments often have limited efficacy or significant side effects, highlighting the need for more targeted and well-tolerated therapies.
Solution
Eumentis is a biopharmaceutical company developing targeted pharmacological treatments for neuropsychiatric conditions. The company utilizes advanced drug formulation techniques to create therapies designed to improve patient outcomes by addressing the underlying mechanisms of mental health disorders. Their approach focuses on developing drugs with enhanced efficacy and reduced side effects compared to existing treatments.
Target Audience
The primary target audience includes individuals suffering from neuropsychiatric conditions and healthcare professionals seeking more effective treatment options.
Features
- Development of targeted pharmacological treatments for neuropsychiatric conditions
- Utilization of advanced drug formulation techniques